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INTRODUCTION
Pain is defined by the International Association for the
Study of Pain as an unpleasant sensory and emotional
experience associated with actual or potential tissue
damage or expressed in terms of such damage. Recogni-
tion of the presence of pain and assessment of the severity
of pain are essential for optimal management and are
integral steps towards appropriate treatment of pain in
animals with (and without) neurological disease. Poorly
managed pain is a significant contributor to morbidity
and mortality, has adverse welfare implications and
delays the return to normal function. Good pain
management relies on regular pain assessment and
includes the administration of analgesic drugs (419). 
The aims of pain treatment are to:
• Inhibit the neuroendocrine stress response, which
may compromise recovery.
• Maintain tissue perfusion.
• Allow restful sleep.
• Encourage mobility.
• Improve appetite.
• Attenuate peripheral and central sensitization.
A plethora of drugs exist that can be used alone or in
combination to manage pain in animals with neurologi-
cal disease. Analgesic therapy must be tailored to each
individual animal based on the cause, duration and
severity of pain, the level of consciousness, the presence
of coexisting diseases and the impact of expected 
side-effects (420, p. 559). This chapter describes specific
considerations for selecting analgesic agents for pain
management of animals with acute neurological disease
and provides examples of analgesic regimens that may be
suitable for these patients. The physiology of pain and
the pharmacology of analgesic drugs are beyond the
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! 419 (a) A dog following hindlimb amputation with
inadequate analgesia. (b) The obvious difference in this
animal’s behaviour is demonstrated after adequate
analgesia was provided.
scope of this book, but a good understanding of both is
vital to ensure optimal pain management (see Further
reading). Furthermore, familiarity with available drugs
will guide the clinician’s decision making.
Painful stimuli may cause an acute pain response and
poorly managed pain can lead to neurophysiological
changes that are permanent. Furthermore, certain types
of pain are particularly difficult to manage and require a
multimodal approach. The clinician should be prepared
to trial therapy and assess the response before commit-
ting to a long-term plan. Neuropathic pain is particular-
ly difficult to manage and is often not responsive to
opioids. It is produced by peripheral and central sensiti-
zation and may be present as allodynia or hypersensitivi-
ty (Table 107). It may be continuous or sporadic and is
described as burning, shooting, tingling or electric in
nature.
Pain assessment
Accurate assessment of pain in animals is difficult. In
animals with acute neurological disease it is even more
challenging, especially if a patient is moribund or
depressed. Conversely, physical examination may reveal
tachycardia, tachypnoea and hypertension, which com-
plicates objective assessment of autonomic nervous
system activity. These cases are easy to misinterpret
and concern about the adverse effects of analgesic drugs
may influence clinical decision making. Given the scope
and variability of responses to painful stimuli in human
patients, every effort must be made to perform a thor-
ough pain assessment in each animal patient and treat
accordingly. Furthermore, assessment of the response to
therapy is essential to ensure that pain is adequately and
continuously controlled. 
In human medicine, self-reporting of pain is the gold
standard method of pain assessment. In veterinary medi-
cine, pain assessment has been performed somewhat
subjectively or by applying pain scales used in humans.
These include simple descriptive scales, numerical rating
scales and visual analogue scales. There are inherent lim-
itations with each of these scales; they are one-dimen-
sional and they have been shown to be unreliable in the
setting of acute postoperative pain in dogs. They have,
however, had their place in the evolution of pain assess-
ment in animals and have contributed to the understand-
ing of the complexity of the pain experience. 
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Table 107 Neuropathic pain
TERMINOLOGY DEFINITION
Allodynia A pain response to a non-painful
stimulus. This is usually localized to the
area of the initial injury
Hypersensitivity An exaggerated pain response to a
painful stimulus. This phenomenon
occurs as a result of ‘sensitization’ 
Peripheral ‘Wind up’ of peripheral nociceptors 
sensitization leading to an exaggerated pain
response to stimulation
Central ‘Wind up’ of central nociceptors
sensitization leading to generalized exaggerated 
pain response to stimulation
Table 108 The multiple steps of the
nociceptive pathway
TERMINOLOGY DEFINITION
Noxious stimulus A mechanical, chemical or thermal
stimulus that causes pain. Pain is the
sensory and emotional experience
associated with actual or potential
tissue damage resulting from a noxious
stimulus
Transduction Processing the noxious stimulus from
the peripheral site to the sensory nerve
endings
Transmission Signalling along sensory nerves to the
central nervous system. Sensory nerves
may be small myelinated A fibres
associated with sharp mechanical-type
stimuli or unmyelinated C fibres
associated with dull, burning or longer
lasting pain
Modulation Alteration of the incoming signal by
synapsing in the dorsal horn of the
spinal cord. Neurotransmitters are
involved in the propagation of ongoing
impulses in the central nervous system.
Synapses within the grey matter of the
spinal cord also connect with the
ventral horn to complete the reflex arc.
This manifests as a withdrawal
response to a noxious stimulus
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" 420 The different classes of analgesic
drugs interfere with the pain process at
different points and a multimodal approach
is invariably most appropriate. The sites of
action of each class of medication are
highlighted. (See also Table 108.)
The only validated pain scoring system for acute pain
in dogs is the Glasgow Composite Measure Pain Scale
(GCMPS), which is a multidimensional scale taking into
account not just the intensity of pain, but its conse-
quences. The GCMPS is based on psychometric princi-
ples that are well established in human medicine for the
measurement of complex constructs such as intelligence,
pain and quality of life. It categorizes and weights 
spontaneous and evoked behaviour and interactive and
clinical observations (comfort, vocalization, mobility,
demeanour, posture, attention to surgical wound and
response to touch), resulting in a composite score. It is
practical in a clinical setting and easy to become familiar
with and use. As it forces the assessor to evaluate behav-
iour that may be associated with pain and draw conclu-
sions about whether or not the animal requires additional
analgesia, it contributes to improved pain management.
A short form of the GCMPS for dogs suffering acute
postoperative pain has been developed for use in a clini-
cal setting where the emphasis is on speed, ease of use and
guidance for provision of analgesia as opposed to precise
measurement of pain in a research environment. The
short form comprises six behavioural categories (vocal-
ization, mobility, demeanour, posture, attention to
surgical wound and response to touch). The maximum
pain score is 24 (or 20, if mobility is impossible to assess)
and it is reported that a clinical decision point for
analgesia gave an intervention level of 6/24 (or 5/20 if
mobility could not be assessed). 
Analgesic drugs
Analgesic drugs fall into the following categories:
• Opioids.
• NSAIDs.
• Local anaesthetics.
• Alpha-2 adrenoceptor agonists (e.g. medetomidine).
• N-methyl-D-aspartate antagonists (e.g. ketamine).
• Miscellaneous drugs (e.g. gabapentin, tramadol,
nitrous oxide).
Most analgesic drugs will diminish pain; they are
hypoalgesic in effect, rather than entirely abolishing it.
The effects are usually dose dependent and an under-
standing of nociceptive pathways, pain transmission,
modulation and perception, the chemical mediators of
pain and inflammation and their impact on pain
processing will help the decision-making process (420
and Table 108). The different classes of analgesics 
interfere with the pain process at different points and a
multimodal approach is invariably most appropriate.
Transmission
Local anaesthetics
Transduction
Opioids
NSAIDs
Alpha-2 agonists
Tramadol
Noxious stimulus:
mechanical,
chemical, thermal
Perception
Opioids
Alpha-2 agonists
Tramadol
Projection
Modulation
Opioids
NSAIDs
Alpha-2 agonists
Tramadol
INTRACRANIAL DISEASE
Overview
Management of pain in animals with intracranial disease
is important from a welfare perspective and because pain
itself may increase ICP. This occurs because of sympa-
thetic nervous system-modulated increases in BP. 
Considerations 
• Cerebral perfusion. Selected analgesic drugs and
management techniques should have little impact
on regulation of CBF. Minimal depression of the
cardiovascular and respiratory systems is important
for maintaining adequate cerebral perfusion and
oxygenation while minimizing secondary neuronal
injury. Hypoventilation and consequent hyper-
capnia may increase CBF and therefore increase
ICP, while hyperventilation and hypocapnia may
cause cerebral vasoconstriction and compromise
CBF. Higher doses of opioids may contribute to
hypoventilation through respiratory depression,
while pain may cause either hypoventilation if chest
excursions are uncomfortable or hyperventilation if
the pain is poorly managed. Close monitoring of
pulmonary function and careful adjustment of doses
are required to provide appropriate analgesia
without respiratory depression.
• Neurological assessment. Analgesic drugs often
cause tranquillization or sedation. Caution should
be exercised if these side-effects are likely to impede
assessment and mask neurological deterioration.
Low doses of short-acting drugs are preferable and
a neurological examination should be performed
prior to the administration of any medication. 
• Severity of pain. As nociceptors are present in the
meninges and skull, the severity of pain will depend
on involvement of these structures in the disease
process. Animals with meningitis (421) or skull
fractures (422) are expected to suffer from severe
pain and should be treated accordingly. Animals
with concurrent trauma to other body systems are
also expected to suffer severe pain.
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! 421 Meningitis is suspected based on the meningeal
enhancement present in this dorsal T1-weighted post-
contrast MR image (arrows). This condition can be
extremely painful. (Photo courtesy Victoria Johnson)
! 422 Radiograph of a frontal bone fracture (arrow) in a
dog. This lesion would be expected to contribute to the
pain present in the animal following its head trauma.
(Photo courtesy Victoria Johnson)
Drug selection
Opioids 
Opioids are often administered to patients with intra-
cranial disease. A summary of the characteristics and dose
regimes of commonly used opioids is presented in
Table 109.
Full mu agonist opioids can be reversed in the event
of undesirable side-effects. The potential complications
of opioid administration, particularly important to
animals with intracranial disease, include bradycardia
(with potential hypotension) and respiratory depression
(with associated hypercapnia). Hypotension associated
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Table 109 Opioid analgesic agents used for perioperative pain control in dogs and cats with 
neurological disease 
AGENT ADVANTAGES DISADVANTAGES DOSE
Morphine
Methadone
Oxymorphone
(US)
Hydromorphone 
(US)
Pethidine
(meperidine US)
Fentanyl
Remifentanil
Tramadol
Buprenorphine
Butorphanol
* Where a dose range is given, the lower doses are recommended for IV administration (where specified) or IM
injection in depressed animals and the higher doses for IM administration in alert animals/animals in pain.
** Cats may have slower metabolism and may require less frequent administration.
CRI = continuous rate infusion.
Excellent analgesia (full mu agonist).
Can be infused intravenously
Excellent analgesia (full mu agonist).
Moderate duration of action.
Antagonizes NMDA receptors 
Excellent analgesia (full mu agonist)
Excellent analgesia (full mu agonist)
Good analgesia (full mu agonist)
Excellent analgesia (full mu agonist).
Short duration of action (15–20
minutes). Suitable for infusion
Excellent analgesia (full mu agonist).
Short duration of action (3 minutes).
Suitable for infusion
Analgesia for moderate pain.
Capsules and syrup available for oral
administration
Long duration of action (6–8 hours).
May provide more analgesia than
morphine in cats 
Good sedative
0.1–0.4 mg/kg IV/IM*
q2–6h** CRI: 0.05–0.1
mg/kg/hour
0.1–0.4 mg/kg IV/IM*
q2–6h**
0.05–0.2 mg/kg 
IV/IM
0.05–0.2 mg/kg 
IV/IM
2–5 mg/kg IM/SC
q1–2h**
CRI: 3–24 µg/kg/hour;
transdermal patches:
2–5 µg/kg/hour
CRI: 3–24 µg/kg//hour
1–2 mg/kg PO/IM/IV
q6–12h
dog: 0.006–0.01 mg/kg
IV/IM/SC* q6–8h;
cat: 0.005–0.01 mg/kg
IV/IM q4–8h.
0.05–0.4 mg/kg IV/IM*
Nausea and vomiting may occur, but are
more likely if given to a pain-free animal.
Histamine release is reported following
rapid IV injection
Pharmacokinetics in small animals unclear.
May accumulate with repeated dosing
Bradycardia, respiratory depression,
sedation occur at conservative doses
Hyperthermia associated with >0.1 mg/kg.
Vomiting (especially with SC injection)
Potent releaser of histamine when given
IV. Pain on IM injection. Large volume.
Short duration of action (1–2 hours)
High doses cause respiratory depression
and bradycardia
Short duration of action (3 minutes).
Higher doses cause respiratory depression
and bradycardia
May cause nausea, vomiting, dizziness.
Increases risk of seizures in susceptible
patients. Use cautiously with head injuries
Analgesia for moderate pain (partial mu
agonist). Prolonged onset of action (30–60
minutes)
Analgesia for mild pain (kappa agonist).
Short duration of action (1–2 hours).
mu receptor antagonist
with opioid-induced bradycardia is not common in
normovolaemic patients with normal myocardial
function. Often, the arterial BP remains stable or
improves as the increased time during diastole associated
with the slight reduction in heart rate allows for
improved ventricular filling and an increased stroke
volume. Conservative doses of opioids are unlikely to
cause significant respiratory depression in normal dogs
and cats, but in those with increased ICP the effects may
be more marked. Care should be taken and therefore the
adequacy of ventilation should be closely monitored.
Opioids are also reported to cause pupillary constriction
in dogs and pupillary dilation in cats (423), which has the
potential to interfere with neurological assessment. In
conscious animals these side-effects do not appear to be a
problem at the low doses used clinically. However, in
animals with CNS depression, these side-effects can be
exacerbated. 
Animals in severe pain, without pre-emptive 
analgesia (e.g. trauma)
The use of short-acting reversible opioids, such as
fentanyl or remifentanil, is preferred in patients in severe
pain. These drugs have a relatively fast onset and short
duration of action, giving them a pharmacokinetic profile
suitable for infusion. The infusion rate can therefore
be titrated to achieve the desired clinical effect. A balance
between adequate analgesia and minimal CNS, cardio-
vascular and respiratory depression (and increase in
PaCO2) must be achieved. Patients with high ICP may
be extremely sensitive to the sedative, cardiovascular and
respiratory depressant effects of opioids, so great care
should be taken and conservative doses should be admin-
istered in the first instance. The authors have observed
markedly reduced mentation using low infusion rates of
fentanyl. It is recommended that infusions of fentanyl
are started as low as 1 µg/kg/hour in animals with head
trauma and increased gradually to achieve the desired
level of pain management without causing further dete-
rioration in mentation. When analgesia cannot be
achieved without respiratory depression, the application
of IPPV (manual or mechanical) will be required to
maintain normocapnia. 
Animals with moderate to severe pain 
(e.g. postoperative period), having received pre- 
and intraoperative analgesia
Intermittent dosing of full mu receptor agonists (e.g.
methadone, 0.1–0.4 mg/kg IM) may be adequate for
animals with severe to moderate pain. However, pain
management can only be achieved by maintaining a
stable therapeutic plasma concentration of drug. This in
turn ensures a stable, effective (e.g. brain or peripheral
nociceptor) concentration of drug. To achieve a stable
plasma concentration of opioid, an infusion that can be
adjusted according to clinical effect is best. Intermittent
‘bolus’ dosing will cause periods of relative overdose and
periods of relative underdose. Morphine and other
opioids that may induce emesis should not be used if
there is any contraindication to vomiting (e.g. raised
ICP). The use of tramadol for perioperative analgesia is
currently popular, but there are only a few reports in the
literature documenting its use and efficacy in dogs.
While it may be appropriate for animals in moderate to
severe pain, it is the authors’ opinion that it should be
reserved for use as an adjunct to an analgesic protocol. A
reported side-effect of tramadol in humans is seizures,
and while this seems to be a risk for veterinary patients as
well, it is unknown how significant a problem this may
be. If the patient is receiving other medication that affects
the reuptake of serotonin, drug interactions should be
taken into account. In such cases a low dose of tramadol
or an alternative analgesic drug should be used.
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! 423 Pupillary dilation in a cat after 
premedication with an opioid. 
Animals with mild pain
Mild pain can be managed with drugs such as buprenor-
phine (0.01–0.02 mg/kg IM q4–6h) or pethidine (2–5
mg/kg IM q1–2h). The appropriate interval between
drug administrations will depend on the anticipated
duration of action of an individual drug. It is always
better to aim for a continuum of pain control, so regular
dosing is important. To achieve a continuum, subsequent
doses of drug should be administered before the plasma
concentration of the drug has decreased. Pethidine is a
full mu agonist, but it does not produce analgesia compa-
rable to morphine, methadone or other full mu agonists.
It is often associated with an increase in heart rate as it has
an atropine-like structure. Pethidine should only be
given intramuscularly as the potential for histamine
release following intravenous injection is high. Further-
more, pain associated with intramuscular injection and
the frequent dosing required for continuous analgesia
make pethidine a less desirable option for pain manage-
ment compared with other opioids. 
Other agents
A summary of other agents available for use in animals
with neurological disease is presented in Table 110.
NSAIDs are also useful, but if any contraindication is
identified (e.g. circulatory shock, coagulopathies, gastric
mucosal bleeding, corticosteroid administration, renal
disease), they should be avoided. Ketamine should
be avoided in patients with intracranial disease and
associated increased ICP, as they may be exacerbated by
ketamine. Alpha-2 adrenoceptor agonists should be used
with extreme caution, as their vasoconstrictive effects
may further compromise CBF. Corticosteroid adminis-
tration may contribute to pain management in certain
disease processes (e.g. meningitis or neoplasia associated
with marked peritumoural oedema) through their anti-
inflammatory action. However, corticosteroids may
potentiate neuronal ischaemia in a hypoxic environment
(see Chapter 20).
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Table 110 Non-opioids used as part of pain management in animals with spinal disease
AGENT ADVANTAGES DISADVANTAGES DOSE REGIMEN
Benzodiazepines:
diazepam,
midazolam
Phenothiazine 
tranquillizers:
acepromazine
Alpha-2 agonists:
medetomidine,
dexmedetomidine
NMDA antagonists:
ketamine,
amantadine
Muscle relaxation
Anxiolysis, sedation 
Sedation, muscle relaxation,
analgesia. Dexmedetomidine 
is associated with fewer
cardiovascular side-effects
than medetomidine
Analgesia. May be useful to treat
neuropathic pain. Interferes with
central sensitization. Reverse
tolerance associated with
prolonged opioid administration
Diazepam: 0.1–0.2 mg/kg
IV/PO. Midazolam:
0.1–0.4 mg/kg IV/IM
0.01–0.05 mg/kg IV/IM
Medetomidine: bolus,
1–2 µg/kg IV up to 3–5 µg/kg
IM; CRI, 0.5–3 µg/kg/hour.
Dexmedetomidine: Bolus,
1 µg/kg IV; CRI, 0.5–1
µg/kg/hour
Ketamine: CRI,
5–10 µg/kg/minute (can be
used with morphine or
lidocaine CRI). Amantadine:
3–5 mg/kg PO q24h
Disinhibition in healthy animals.
Respiratory depression in animals with
underlying respiratory disease/
insufficiency
Hypotension; avoid in hypovolaemia.
Contraindicated in carbamate and
organophosphate poisoning
Adverse cardiovascular effects: avoid in
animals with heart disease, hypo-
volaemia. Hyperglycaemia: avoid in
diabetics and head trauma. High
incidence of vomiting in cats
Dysphoria associated with accumulation
of norketamine with prolonged infusion,
therefore requires dose reduction with
time. Arrhythmogenic: avoid in chest
trauma. Increased skeletal muscle tone
may potentiate pain due to muscle
spasm. Pain on IM/SC injection. Cerebellar
dysfunction reported anecdotally in some
breeds of cat (Continued)
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Table 110 Non-opioids used as part of pain management in animals with spinal disease (continued)
AGENT ADVANTAGES DISADVANTAGES DOSE REGIMEN
Tricyclic 
antidepressants:
amitriptyline
Lidocaine
Gabapentin
May be useful in the treatment of
neuropathic pain. Blocks nor-
adrenaline and serotonin reuptake
in the brain, increasing the effect
of these neurotransmitters
Analgesia. May be useful in
neuropathic pain
Supplementary analgesia for
neuropathic pain
1–2 mg/kg PO q12h
Initial bolus of 2 mg/kg
followed by 20–50
µg/kg/minute 
Titrate dose from 2 mg/kg up
to 10–20 mg/kg PO q8–12h 
Vomiting and diarrhoea, excitability,
arrhythmias. Consider drug interactions if
using anaesthetics or antiepileptics.
Enhanced sedation if used with other
sedating drugs
Sedation may interfere with mobility.
Myocardial depression can cause hypo-
tension in unstable patients. Vomiting
reported. DO NOT USE IN CATS
Sedation and ataxia
SPINAL DISEASE
Considerations
• Neuronal function. Aiming to preserve neuronal
function by maintaining perfusion and oxygenation
is vital. Agents that cause excessive depression of
cardiovascular and pulmonary functions should be
avoided. Arterial BP and adequacy of ventilation
(using a capnograph) should be monitored closely.
• Pain. Pain associated with spinal disease (424) is
likely to be severe, necessitating the use of potent
analgesic drug combinations by continuous
infusion.
• Anxiolysis. Anxiety in weak or paralysed animals
may decrease the pain threshold. The judicious
administration of anxiolytics is a useful part of pain
management in haemodynamically stable animals.
• Muscle relaxation. The administration of muscle
relaxants is useful in reducing pain associated with
muscle spasm. (Note: Do not use in animals with
unstable fractures.) 
• Neuropathic pain. When present, neuropathic
pain is often resistant to opioid analgesia and
requires a multimodal analgesic regime. 
• Multimodal analgesia. A combination of analgesic
agents can be administered concurrently to
optimize pain management and minimize the
frequency and severity of side-effects associated
with individual agents. 
Drug selection
Opioids
Due to the severity of pain in most animals with spinal
disease, opioid analgesics are often the best choice. The
advantages and disadvantages of commonly used opioids
and appropriate dose rates are described in Table109. 
Animals in severe pain (e.g. spinal trauma)
As previously described for animals with intracranial
disease (see above), the use of short-acting reversible
opioids, such as fentanyl or remifentanil, is preferred in
animals with severe pain (e.g. trauma victims with multi-
ple organ damage and orthopaedic injury).
! 424 Animals with spinal disease, such as the one in this
picture, will be in pain and require administration of
analgesic agents.
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The transdermal delivery of drug from a patch
applied to the skin (e.g. fentanyl patches, 425) may
provide a useful adjunct to perioperative analgesia. It may
take up to 24 hours for therapeutic plasma concentra-
tions to be achieved, so analgesia will be required until
this time. The delay is shorter in cats than in dogs.
Because there is also marked individual variation in
absorption and, therefore, plasma concentrations
achieved, fentanyl patches should not be relied on as the
Stable animals requiring intensive pain control 
During the immediate post-trauma or post-surgical
period, the continuous infusion of opioids (e.g. fentanyl
or morphine) is more likely to prevent breakthrough
pain. Opioid infusions can be combined with other
agents to achieve multimodal pain management (e.g. an
opioid in combination with ketamine and/or lidocaine).
Infusion rates for each of the individual drugs are
provided in Tables 109 and 110. 
e
a b
c
! 425 Steps for placement of a fentanyl patch. (a) Clip
the skin prior to placement of the patch. (b) Wipe the
skin with a dry swab only. (c) Wear gloves when
positioning the patch. In this case two patches are being
used (25 µg/hour and 50 µg/hour). (d) Ensure even
adherence to the skin with gentle digital pressure. 
(e) Cover the patches with a light adhesive dressing and
label with the name of the drug and the time and date 
of application.
d
sole method of providing analgesia. Buprenorphine
patches are also available and should be used with the
same caveats as fentanyl patches. Patches should not be
cut in half. If a lower dose is required, then creating a
barrier between the patch and the skin is most appropri-
ate. It is best to place the patch on a clipped area of skin
out of reach of the patient. The lateral thorax, dorsum or
neck may be appropriate. 
Stable animals requiring less intensive pain control
When less intensive management of the animal is
required, intermittent administration of full mu opioids
such as methadone or morphine can be used. Although
vomiting is less likely in animals in pain, the use of mor-
phine is generally avoided in animals with cervical injury
where violent movements associated with vomiting can
cause further injury to an unstable spinal lesion. In 
addition, recumbent animals that vomit may not be able
to clear vomitus from the pharynx and mouth, predispos-
ing to airway obstruction and aspiration. 
Other agents
A variety of other agents can be used in conjunction with
opioids to improve pain management. A summary of
these agents can be found in Tables 110 and 111.
Non-steroidal anti-inflammatory drugs
NSAIDs may be used to decrease inflammatory pain and
they are potent analgesics in their own right. The cyclo-
oxygenase inhibitors carprofen, meloxicam and meclo-
fenamic acid are registered for perioperative use (Table
111). The lipoxygenase and cyclo-oxygenase inhibitor
tepoxalin was available to the veterinary market, but it
has been associated with an increased incidence of
adverse side-effects. 
Concurrent administration of NSAIDs and cortico-
steroids is contraindicated due to increased risk of gastro-
intestinal ulceration and haemorrhage, therefore the use
of NSAIDs is best delayed until it has been decided
whether the patient will benefit from corticosteroid
therapy. For animals receiving either steroids or
NSAIDs, concurrent administration of gastrointestinal
protectants may help reduce the incidence of gastro-
intestinal ulceration. 
Muscle relaxants
Benzodiazepines (diazepam or midazolam, 0.25–0.5
mg/kg PO q6–8h) may provide a useful adjunct to pain
management in patients with stable spinal injury by alle-
viating muscle spasm, which is commonly observed in
animals with spinal disease. In animals with unstable
spinal lesions (e.g. fractures), skeletal muscle relaxation
may be detrimental as it reduces the splinting effects of
the epaxial muscle. 
Alpha-2 agonists, such as medetomidine, can also be
used to provide muscle relaxation. In addition, these
agents are analgesic. Because of sedative and cardio-
vascular side-effects, these agents are generally limited to
animals that do not have cardiovascular pathology. The
authors have found that infusing medetomidine at
1–3.5 µg/kg/hour is useful in healthy dogs that have pain
or anxiety that is unresponsive to other drugs. As with
benzodiazepines, these agents should be avoided in
animals with unstable spinal fractures.
Anxiolytics
Acepromazine is an extremely useful agent for anxious
animals with spinal disease. Due to its hypotensive
effects, the use of this agent should be limited to normo-
volaemic and normotensive animals. The side-effects 
are dose dependent; the authors use 0.01–0.05 mg/kg 
to a maximum of 1 mg/kg. Acepromazine is also more
effective if combined with an opioid (e.g. 0.03 mg/kg 
acepromazine with 0.3 mg/kg morphine for sedation).
Trazodone can also be used for this function (see p. 545).
N-methyl-D-aspartate antagonists
Ketamine is becoming increasingly popular as part of a
multimodal analgesic protocol in small animals. Keta-
mine interferes with the process of CNS sensitization
(wind-up), which may manifest as hyperalgesia (exagger-
ated pain response to a painful stimulus) or allodynia
(pain response to a non-painful stimulus) from peripheral
and central sensitization. It plays an extremely important
role in the management of animals with chronic pain,
animals with direct nerve trauma, amputees and trauma
patients. Care is required when using this agent in
trauma patients where the arrhythmogenic effects of 
ketamine may exacerbate myocardial contusions or
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DRUG SIDE-EFFECTS DOSE RATE: DOGS DOSE RATE: CATS
Carprofen
Meloxicam
Meclofenamic acid
ischaemia and associated arrhythmias. At higher doses
the cardiovascular effects of ketamine can become prob-
lematic (increased heart rate and BP). The authors use
2–10 µg/kg/minute by infusion for analgesia (higher end
of dose rate if intraoperatively and lower end if con-
scious). A ‘bolus’ dose of ketamine may be incorporated
into a premedication for cats (5–10 mg/kg) and very dif-
ficult dogs (1–2 mg/kg). Dogs are more prone to the dis-
sociative effects of ketamine, so lower doses should be
used in this species. As part of an induction combination,
ketamine can be given at 5 mg/kg with a benzodiazepine
(e.g. diazepam or midazolam, 0.25–0.5 mg/kg).
Methadone may also act as an antagonist at the
NMDA receptor and this is thought to be especially
beneficial in the treatment of neuropathic pain that may
otherwise be resistant to typical opioids.
Lidocaine 
The effectiveness of this agent in spinal pain has not been
determined. It should, however, be considered if pain is
unresponsive to other agents. It can be administered
either alone or in combination with morphine and/or
ketamine. Infusion of each drug is adjusted to optimize
analgesia but minimize sedation. Lidocaine can depress
cardiovascular function and contribute to hypotension,
therefore it is essential that animals are normovolaemic
and that cardiovascular function is monitored during
administration. It should also be used cautiously in cats
and at lower doses than in dogs, as the former species is
more sensitive to the neuroexcitatory effects of lidocaine. 
Lidocaine patches are also available and may be useful
for topical analgesia prior to attempting vascular access
or for the management of incisional pain. The onset of
action is relatively rapid. (The area should be clipped and
the patch secured in position to avoid inadvertent
ingestion by the patient. Care should also be taken to
avoid heating the area, as this may accelerate absorption
and increase the potential for side-effects.)
Tramadol
Tramadol is an agent with weak mu opioid agonist and
non-opioid analgesic properties. The non-opioid effects
are associated with increased noradrenaline (norepine-
phrine) and 5-hydroxytryptamine (serotonin) at central
neuronal synapses, which reduces the excitability of
spinal nociceptive activity, partly via alpha-2 adrenergic
activity. The activities of the opioid and non-opioid
mechanisms are synergistic, resulting in greater analge-
sia than that expected for each component acting 
separately. The efficacy of tramadol postoperatively in
humans appears to be similar to that of µ opioid agonists.
It can be administered parenterally and enterally. Com-
prehensive clinical studies in animals are currently
lacking. Tramadol has a wide therapeutic margin and
while most dosing is based on anecdotal reports it is
common to use 1 mg/kg q12h or q8h.
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Table 111 Non-steroidal anti-inflammatory drugs
Minimal. Vomiting
Minimal. Diarrhoea
Vomiting and diarrhoea
2 mg/kg PO, SC or IV q12h or
4 mg/kg q24h 
0.2 mg/kg PO, SC or IV q24h
then 0.1 mg/kg q24h
thereafter
1–2 mg/kg PO q24h
2 mg/kg SC once only
0.1–0.2 mg/kg PO or SC
once only. 0.1 mg/kg q24h
for 3 days
Not used
NEUROPATHIC PAIN
Neuropathic pain (426) is classically less responsive to
opioids and difficult to manage. It may occur in patients
with lumbosacral disease, neuropathy, nerve root trauma
and a number of other conditions. Other agents that may
be useful in animals suffering neuropathic pain include
ketamine, amantadine, medetomidine, lidocaine, tra-
madol, gabapentin and tricyclic antidepressants. A
summary of these agents and doses rates are found in
Table 110.
Gabapentin’s mode of action in the treatment of
neuropathic pain is thought to be by prevention of the
release of glutamate in the dorsal horn via interaction
with the alpha-2/delta subunit of the voltage-gated
calcium channels. While gabapentin has been used safely
in dogs, only anecdotal reports of its efficacy have been
published.
NEUROMUSCULAR DISEASE
Considerations 
• Severity of pain. The type of NM disease will
influence the severity of pain and the choice of
analgesic agents. Some conditions may not be
painful, so careful pain assessment is essential.
• Ventilation. Animals with NM disease frequently
have impaired ventilation. This may be exacerbated
by drugs that depress spontaneous ventilation 
(e.g. opioids).
• Vomiting. Animals with NM disease may not be
able to protect their airway. In addition, vomiting
may trigger laryngeal spasm in animals with
tetanus. Agents that predispose to vomiting (e.g.
morphine) should be avoided.
• Sedation. The use of analgesic agents with sedative
properties may exacerbate recumbency and
immobility in animals with NM weakness. In
contrast, sedation can be useful in animals that are
hyperaesthetic (e.g. polyradiculoneuritis). (Note:
Acepromazine is contraindicated in methiocarb and
organophosphate poisoning.)
Drug selection
Any of the drugs used for management of spinal pain can
be used for management of animals with painful NM
disease. The choice will depend on the stability of the
animal and the severity of the pain. 
Regional and local anaesthesia in animals with
neurological disease
While pain associated with intracranial disease and 
generalized NM disease is not amenable to regional
anaesthesia, this modality may be useful for managing
pain associated with trauma to other regions of the body.
Regional anaesthesia may also be used in certain spinal
diseases. Regional and local anaesthesia provide the ulti-
mate in analgesia if the innervation of an area can be iso-
lated and completely desensitized. 
In patients with chest wall trauma, intrapleural or
intercostal nerve blocks are effective as an adjunct to an
analgesic regime. A maximum dose of 2 mg/kg of bupi-
vacaine should be administered every 6 hours. For
intrapleural analgesia this dose may be diluted to increase
the volume or combined with NaHCO3 to minimize the
discomfort associated with the low pH of the solution.
For intercostal nerve blocks, two intercostal spaces either
side of the lesion or surgical wound should be blocked
(five spaces in total). The intercostal nerves cross-inner-
vate, so it is essential to block at least five spaces. The
nerve runs caudal to the rib. Epidural administration of
analgesic drugs will provide additional analgesia in
animals with concurrent pelvic and abdominal trauma
(see Further reading). Epidurals have also been used to
provide analgesia in animals with spinal fractures,
although the use of local anaesthetic by this route, and
consequent motor (and sensory) blockade, should gener-
ally be avoided, as motor function is an essential part of
neurological assessment. Local anaesthetic drug prepara-
tions may be diluted to minimize motor blockade (e.g.
0.25% bupivacaine can be diluted to 0.125%) or ropiva-
caine may be used. Epidural administration of local
anaesthetics should be avoided in haemodynamically
unstable animals as sympathetic nerve blockade will
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exacerbate hypotension. In these cases, epidural admin-
istration of morphine alone (0.1 mg/kg diluted in sterile
saline to the desired volume) can still provide useful
regional analgesia. The volume of injection is a factor
that determines the degree of cranial spread of the drug
and, therefore, the clinical effect. Opioids are lipophilic,
so will spread cranially, but increasing the volume of
injection will facilitate this. As a rule of thumb, 1 ml 
of diluted drug per 4.5 kg to a maximum of 6 ml is
appropriate.
For infiltration of surgical or traumatic wounds, a
combination of lidocaine with NaHCO3 (1 mmol/ml) in
a ratio of 9:1 will help reduce irritation on injection.
Lidocaine 2% can be combined with 0.5% bupivacaine
in a 1:1 ratio to provide a more rapid onset and longer
duration of action. 
Prior to placement of an intravenous or intra-arterial
catheter, a eutectic mixture of local anaesthetic (EMLA)
cream can be applied to the site at least 30 minutes
beforehand. EMLA will facilitate painless placement of a
catheter and is especially useful for arterial catheteriza-
tion in conscious patients. Lidocaine patches are also
useful in this situation. For nasal cannula or urinary
catheter placement, topical application of a local anaes-
thetic, such as xylocaine or lidocaine spray, is helpful if
administered a few minutes beforehand. 
Non-specific aspects of pain management in
animals with neurological disease
• Bedding should be well padded, able to wick
moisture away from the patient, easy to clean and
easy to replace as often as required.
• A comfortable ambient temperature will help
prevent hypothermia or panting.
• A urinary catheter may be necessary to prevent
urinary retention, especially if an epidural has been
administered. Placement of a urinary catheter also
facilitates the measurement of urine output, which
is useful to ensure adequate fluid therapy and renal
function (see Chapters 31 and 2, respectively).
Placement of the urinary catheter must be
performed aseptically. 
• Any wounds should have regular dressing changes.
If dressings are wet or odorous, they should be
changed immediately.
• Patients that require exercise should be managed
carefully by skilled personnel with a good
understanding of the individual patient’s history and
treatments.
• ICUs can be busy places and animals may find it
difficult to sleep quietly and rest. It is important to
provide quiet times with the lights out, so sleep
deprivation does not contribute to morbidity.
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" 426 Neuroanatomy and neurotransmitters involved 
in pain pathways. Descending pathways modulate the
incoming pain sensation, which stimulates glutamate
release.
Spinothalamic tract
Descending serotonin and
norepinephrine tracts
Interneuron containing
enkephalin
Opioid receptors
Dorsal root ganglion
Peripheral process
